Brian Conway, M.D., F.R.C.P.C.
Dr. Conway is also a member of several professional organizations. He is the Chair-Elect of the Canadian Pediatric AIDS Research Group, a council member of both the Canadian Infectious Diseases Society (CIDS) and the Canadian Association for HIV Research (CAHR), and a member of the IAS-USA's resistance testing guidelines panel. He serves on the editorial boards of the Journal of Acquired Immune Deficiency Syndromes and AIDS.
In addition to coordinating HIV teaching for the UBC medical school and supervising several dozen undergraduate, graduate and post-doctoral students over the past decade, Dr. Conway is deeply involved in a range of HIV-related research and clinical practice efforts. These have recently focused on the care of HIV-positive intravenous drug users (developing novel models of care for this unique group), the measurement of HIV drug resistance in clinical practice and the treatment of acute HIV infection.
Dr. Conway has been an invited speaker at many international HIV conferences and meetings, including the 2003 NIDA-sponsored Directly Observed Therapy Symposium and several meetings of the Mexican HIV Association. Most recently, he was one of the organizers of the 2003 Annual Meeting of the Canadian Association for HIV Research. He is a peer reviewer of 13 medical journals and the primary or senior author of more than 120 peer-reviewed publications.
Dr. Conway received his medical education at McGill University, from which he graduated in 1982 before completing his internship and residency at Queen Elizabeth Hospital and Royal Victoria Hospital, respectively. He completed a specialty fellowship in infectious diseases at the University of Manitoba in 1988, and a post-doctoral fellowship in HIV/AIDS at Harvard University in 1990.
Dr. Conway has received, or is receiving, research grants from the following pharmaceutical companies: Abbott Laboratories, Agouron Pharmaceuticals, ALDA Pharma, Allellix Biopharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Chiron, Efamol Research, GlaxoSmithKline, Merck Sharp Dome, Pfizer Pharmaceuticals, Pharmacia & Upjohn, Receptagen, Roche Canada, Roche Diagnostics, Schering Canada and Triangle Pharmaceuticals. He is currently a member of the HIV Scientific Advisory Boards to Agouron Canada and Bristol Myers Squibb Canada, and Chairman of the Scientific Advisory Board of Pharmacor.